Fig. 2From: Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence ScoresOverall survival of patients (2006–2010) who received chemotherapy did not differ significantly from patients who did not receive chemotherapy in this study, with estimated 5-year overall survival of 97.4% vs 97.8% at a median follow-up of 46.4 months (p = 0.89)Back to article page